Cyclacel Pharmaceuticals

OverviewSuggest Edit

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases, particularly those of high unmet medical need, with a vision to improve patient healthcare with orally available innovative medicines. The Company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

TypePublic
Founded1992
HQBerkeley Heights, US
Websitecyclacel.com

Latest Updates

Employees (est.) (Mar 2020)12(-14%)
Revenue (FY, 2018)$150 K
Share Price (Sept 2020)$3.5 (-2%)
Cybersecurity ratingAMore

Key People/Management at Cyclacel Pharmaceuticals

Spiro Rombotis

Spiro Rombotis

President and Chief Executive Officer
David U'Prichard

David U'Prichard

Chairman
Paul McBarron

Paul McBarron

Executive Vice President, Finance and Chief Operating Officer and Secretary
Judy Chiao

Judy Chiao

Vice President, Clinical Development and Regulatory Affairs
Amartya Basu

Amartya Basu

Senior Director, Project Management and Business Development
Show more

Cyclacel Pharmaceuticals Office Locations

Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City
Berkeley Heights, US (HQ)
200 Connell Dr #1500
Dundee City, GB
1 James Lindsay Pl
Show all (2)

Cyclacel Pharmaceuticals Financials and Metrics

Cyclacel Pharmaceuticals Revenue

Cyclacel Pharmaceuticals's revenue was reported to be $150 k in FY, 2018
USD

Net income (Q2, 2020)

(2.2m)

EBIT (Q2, 2020)

(2.5m)

Market capitalization (22-Sept-2020)

16.8m

Closing stock price (22-Sept-2020)

3.5

Cash (30-Jun-2020)

25.3m

EV

(7.4m)
Cyclacel Pharmaceuticals's current market capitalization is $16.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

699.0k69.0k1.1m1.7m1.9m843.0k150.0k

Revenue growth, %

60%12%(57%)

Cost of goods sold

360.0k

Gross profit

339.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

168.0k164.0k161.0k146.0k38.0k212.0k264.0k309.0k396.0k356.0k735.0k512.0k296.0k715.0k139.0k205.0k

Cost of goods sold

72.0k95.0k94.0k89.0k

Gross profit

96.0k69.0k67.0k57.0k

Gross profit Margin, %

57%42%42%39%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.4m16.4m31.1m24.2m20.4m16.5m23.9m17.5m11.9m

Prepaid Expenses

1.2m1.6m3.4m4.6m4.1m2.1m2.3m2.1m

Inventories

182.0k

Current Assets

25.8m18.9m35.2m29.0m24.6m19.6m26.0m19.8m14.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

20.6m27.7m23.6m20.0m17.8m14.1m33.7m34.5m28.2m33.5m26.7m29.4m26.9m22.7m17.1m15.9m18.0m12.7m13.6m26.0m21.7m19.8m19.0m17.9m15.2m13.0m8.9m25.3m

Accounts Receivable

45.0k

Prepaid Expenses

1.7m941.0k1.4m1.6m1.2m2.1m2.7m2.4m4.7m3.4m4.2m5.5m3.5m4.0m4.1m2.8m4.5m4.3m2.5m1.8m3.0m2.9m1.7m2.2m3.0m2.9m2.9m2.6m

Inventories

147.0k165.0k109.0k50.0k
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Cyclacel Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Cyclacel Pharmaceuticals Online and Social Media Presence

Embed Graph

Cyclacel Pharmaceuticals News and Updates

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT –

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

BERKELEY HEIGHTS, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™…

Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET

Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Monday, Nov…

Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

BERKELEY HEIGHTS, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the 4th Annual Da…

Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

Multi-product agreement builds on long-term clinical collaboration in hematological malignancies Multi-product agreement builds on long-term clinical collaboration in hematological malignancies
Show more

Cyclacel Pharmaceuticals Blogs

CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING Content Import Tue, 04/21/2020 - 08:27 CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING 04/21/20 This release is a backfill from a News Wire General BERKELEY HEIGHTS,…

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor  and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2020 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J. , Feb.

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results Content Import Wed, 02/19/2020 - 07:01 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results 02/19/20 This release is a backfill from a N…

Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO &

Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors  and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco Content Import Mon, 01/06/2020 - 07:01 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco 01/06/20 This release is a backfill from a News Wire …
Show more

Cyclacel Pharmaceuticals Frequently Asked Questions

  • When was Cyclacel Pharmaceuticals founded?

    Cyclacel Pharmaceuticals was founded in 1992.

  • Who are Cyclacel Pharmaceuticals key executives?

    Cyclacel Pharmaceuticals's key executives are Spiro Rombotis, David U'Prichard and Paul McBarron.

  • How many employees does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 12 employees.

  • Who are Cyclacel Pharmaceuticals competitors?

    Competitors of Cyclacel Pharmaceuticals include Signia Therapeutics, Akelos and Moderna.

  • Where is Cyclacel Pharmaceuticals headquarters?

    Cyclacel Pharmaceuticals headquarters is located at 200 Connell Dr #1500, Berkeley Heights.

  • Where are Cyclacel Pharmaceuticals offices?

    Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City.

  • How many offices does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 2 offices.